Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/DHX9_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/DHX9_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/DHX9_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/DHX9_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/DHX9_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/DHX9_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/DHX9_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/DHX9_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/DHX9_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003260613 | Thyroid | ATC | type I interferon production | 47/6293 | 95/18723 | 9.81e-04 | 5.21e-03 | 47 |
GO:000181924 | Thyroid | ATC | positive regulation of cytokine production | 189/6293 | 467/18723 | 1.00e-03 | 5.31e-03 | 189 |
GO:005109122 | Thyroid | ATC | positive regulation of DNA-binding transcription factor activity | 111/6293 | 260/18723 | 1.32e-03 | 6.88e-03 | 111 |
GO:004573911 | Thyroid | ATC | positive regulation of DNA repair | 37/6293 | 73/18723 | 1.89e-03 | 9.24e-03 | 37 |
GO:004508813 | Thyroid | ATC | regulation of innate immune response | 94/6293 | 218/18723 | 2.05e-03 | 9.71e-03 | 94 |
GO:003272811 | Thyroid | ATC | positive regulation of interferon-beta production | 22/6293 | 39/18723 | 2.84e-03 | 1.29e-02 | 22 |
GO:00062756 | Thyroid | ATC | regulation of DNA replication | 50/6293 | 107/18723 | 3.25e-03 | 1.46e-02 | 50 |
GO:00327608 | Thyroid | ATC | positive regulation of tumor necrosis factor production | 48/6293 | 103/18723 | 4.14e-03 | 1.76e-02 | 48 |
GO:00713601 | Thyroid | ATC | cellular response to exogenous dsRNA | 12/6293 | 18/18723 | 4.22e-03 | 1.79e-02 | 12 |
GO:00457408 | Thyroid | ATC | positive regulation of DNA replication | 22/6293 | 40/18723 | 4.32e-03 | 1.80e-02 | 22 |
GO:19035576 | Thyroid | ATC | positive regulation of tumor necrosis factor superfamily cytokine production | 49/6293 | 107/18723 | 5.79e-03 | 2.34e-02 | 49 |
GO:003239216 | Thyroid | ATC | DNA geometric change | 42/6293 | 90/18723 | 6.81e-03 | 2.70e-02 | 42 |
GO:00326086 | Thyroid | ATC | interferon-beta production | 28/6293 | 56/18723 | 8.12e-03 | 3.13e-02 | 28 |
GO:00326486 | Thyroid | ATC | regulation of interferon-beta production | 28/6293 | 56/18723 | 8.12e-03 | 3.13e-02 | 28 |
GO:006096815 | Thyroid | ATC | regulation of gene silencing | 38/6293 | 81/18723 | 8.77e-03 | 3.33e-02 | 38 |
GO:004333111 | Thyroid | ATC | response to dsRNA | 27/6293 | 55/18723 | 1.24e-02 | 4.38e-02 | 27 |
GO:003272711 | Thyroid | ATC | positive regulation of interferon-alpha production | 13/6293 | 22/18723 | 1.25e-02 | 4.38e-02 | 13 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DHX9 | SNV | Missense_Mutation | novel | c.1531N>T | p.Asp511Tyr | p.D511Y | Q08211 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A7-A5ZW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | CR |
DHX9 | SNV | Missense_Mutation | | c.2173N>T | p.Val725Phe | p.V725F | Q08211 | protein_coding | deleterious(0.04) | probably_damaging(0.998) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DHX9 | SNV | Missense_Mutation | | c.3280C>T | p.His1094Tyr | p.H1094Y | Q08211 | protein_coding | tolerated(1) | benign(0.157) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
DHX9 | SNV | Missense_Mutation | | c.2714G>A | p.Arg905Gln | p.R905Q | Q08211 | protein_coding | deleterious(0.02) | probably_damaging(0.984) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DHX9 | SNV | Missense_Mutation | novel | c.2202N>C | p.Gln734His | p.Q734H | Q08211 | protein_coding | deleterious(0) | probably_damaging(0.95) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
DHX9 | SNV | Missense_Mutation | rs754675901 | c.1582C>T | p.Arg528Cys | p.R528C | Q08211 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DHX9 | SNV | Missense_Mutation | | c.176G>A | p.Ser59Asn | p.S59N | Q08211 | protein_coding | tolerated(0.22) | benign(0.281) | TCGA-BH-A1F0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
DHX9 | SNV | Missense_Mutation | novel | c.929N>G | p.Leu310Arg | p.L310R | Q08211 | protein_coding | deleterious(0.01) | probably_damaging(0.97) | TCGA-C8-A8HQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
DHX9 | SNV | Missense_Mutation | | c.2588G>A | p.Arg863His | p.R863H | Q08211 | protein_coding | deleterious(0.05) | probably_damaging(0.993) | TCGA-D8-A1JE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamicin | SD |
DHX9 | SNV | Missense_Mutation | | c.67N>G | p.Ile23Val | p.I23V | Q08211 | protein_coding | tolerated(0.92) | benign(0.028) | TCGA-E9-A1NI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |